GLP-1 analogues, including Tirzepatide (Mounjaro), have recently been licensed for weight management in adults with obesity or overweight with comorbidities. While NICE has approved Tirzepatide for use under specific criteria, they have not been commissioned for prescribing or monitoring in Welsh General Practice. 

Until a national or local supplementary service is negotiated, GPs should not initiate or monitor GLP-1 analogues for weight loss. Prescribing for weight management remains the remit of specialist services only.

Private prescribing of GLP-1 analogues is becoming increasingly commonplace and generates requests to practices for access to patient medical information. This guidance seeks to assist practices in appropriately managing these requests, taking account of professional guidance and patient safety considerations. The guidance also includes a template letter for practices to respond to requests for medical information following a private consultation